Brain metastases from primary tumors. Volume 3, Epidemiology, biology, and therapy of melanoma and other cancers / edited by M.A. Hayat.

Includes bibliographical references and index.

Introduction -- The management and biology of metastatic cancers to the brain -- Melanoma metastases are underrepresented in cerebellum compared with metastases from colorectal cancers -- Risk reductions of recurrence and mortality in melanoma patients using ifn-[alpha] -- Brain metastases from melanoma -- Pathobiology of brain metastases : molecular mechanisms -- Role of cdkn2a mutations and other relevant genes in melanoma predisposition -- The role of the receptor for advanced glycation end products in malignant melanoma -- Hydrogen sulfide pathway and cancer -- Brain metastasis from esophageal cancer -- Treatment of metastatic melanoma patients bearing c-kit mutation using imatinib mesylate -- Optimal selection of targeted therapies for melanoma patients : role of the mitogen-activated protein kinase pathway -- Patients with brain metastases from melanoma : treatment with surgery and radiotherapy -- The risks and advantages of whole brain radiation therapy in patients with brain metastases -- Gastrointestinal stromal tumors with intracranial metastasis : treatment strategy and review of the literature -- Brain metastases from breast cancer in patients receiving trastuzumab -- Brain metastases from cutaneous melanoma : biology and its implications for more rational therapeutic approaches -- Treatment of brain metastases from ovarian and endometrial carcinomas using stereotactic radiosurgery -- Prognostic factors for survival in melanoma patients with brain metastases -- Management of melanoma therapy-associated toxicities -- Brain metastases from breast cancer : focus on risk factors, treatment, and clinical outcome.

Brain Metastases from Primary Tumors Volume Three: Epidemiology, Biology, and Therapy of Melanoma and Other Cancers provides a comprehensive overview of the metastasis of cancer, the main cause of approximately 90% of cancer associated deaths, yet the mechanisms governing this clinically important process remain poorly understood. Melanoma is the third most common diagnosis among patients with brain metastases, after lung and breast cancer. Approximately 75% of patients with metastatic melanoma develop brain metastases during the course of their disease. Although tumorigenesis of melanoma remains poorly understood, recent advances in gene expression profiling have revealed molecular mechanisms of this deadly disease. In addition, high-throughput gene expression has many advantages over techniques in cancer transcriptomic studies and has led to the discovery of numerous diagnostic, prognostic, and therapeutic targets, which are also detailed in this book. The book discusses the link between primary tumors and brain metastasis of melanoma, including molecular mechanisms, treatment options, prognosis, and general applications. Comprehensive chapters discuss systemic therapy, integrin inhibitors, stereotaxic radiosurgery, and more, making this book a great resource for neurooncologists, neurosurgeons, neurologists, and cancer researchers.

Online resource; title from resource home page (ClinicalKey, viewed August 10, 2017).

Elsevier Elsevier ClinicalKey eBooks - WAYFless access